{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:36Z","timestamp":1792815396344,"version":"4.5.0"},"reference-count":60,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Olema Oncology"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.1080\/14796694.2025.2608863","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:26:07Z","timestamp":1767065167000},"page":"157-166","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["OPERA-01: a phase III study of palazestrant for ER+, HER2\u2013 advanced breast cancer after CDK4\/6 inhibitor therapy"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"first","affiliation":[{"name":"Gustave Roussy","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-8307","authenticated-orcid":false,"given":"Meritxell","family":"Bellet Ezquerra","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, University of Genova","place":["Genova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-5228","authenticated-orcid":false,"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-865X","authenticated-orcid":false,"given":"Jane","family":"Meisel","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2286","authenticated-orcid":false,"given":"Arlene","family":"Chan","sequence":"additional","affiliation":[{"name":"Curtin University, Breast Clinical Trials Unit, Hollywood Private Hospital","place":["Nedlands, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianqing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Olema Oncology","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"de Kermadec","sequence":"additional","affiliation":[{"name":"Olema Oncology","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-3871","authenticated-orcid":false,"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center","place":["Dallas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_7_4_1","volume-title":"Breast cancer facts and figures 2022\u20132024","author":"American Cancer Society","year":"2022","unstructured":"American Cancer Society. Breast cancer facts and figures 2022\u20132024. Atlanta: American Cancer Society, Inc; 2022."},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3462"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18160"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18176"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.56142"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113989"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111322"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3920"},{"key":"e_1_3_7_12_1","unstructured":"FASLODEX\u00ae (fulvestrant). Prescribing information. AstraZeneca; 2019. Available from: https:\/\/medic.alinformation.astrazeneca-us.com\/home\/prescribing-information\/faslodex.html"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-017-0046-2"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.06.005"},{"key":"e_1_3_7_15_1","unstructured":"Surveillance epidemiology and end results program [Internet]. (WA) (DC): National Cancer Institute; [cited 2025 May 22]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=622&data_type=1&graph_type=2&compareBy=stage&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&hdn_rate_type=1&hdn_sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=1#resultsRegion0"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834015608993"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-1246-5"},{"key":"e_1_3_7_18_1","unstructured":"National comprehensive cancer network. Breast cancer guidelines (Version 4). 2025 [cited 2025 May 22]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01392"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2023.26.e29"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70001"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.04.003"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0620-6"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.117"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.012"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02049-y"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410858"},{"key":"e_1_3_7_31_1","unstructured":"Pfizer Inc. Arvinas and Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial [Press release]. 2025 Mar 11. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/arvinas-and-pfizer-announce-positive-topline-results-phase"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_7_33_1","unstructured":"US Food and Drug Administration. FDA approves elacestrant for ER-positive HER2-negative ESR1-mutated advanced or metastatic breast cancer [Press release]. 2023 Jan 27. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215397"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0351"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221113694"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208501200"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068537"},{"key":"#cr-split#-e_1_3_7_42_1.1","unstructured":"Olema Pharmaceuticals Inc. A dose escalation\/expansion study of oral OP-1250 in subjects with advanced and\/or metastatic hr+ HER2- breast cancer. Clinicaltrials.Gov Identifier: nCT04505826. [Updated 2023 August 22"},{"key":"#cr-split#-e_1_3_7_42_1.2","unstructured":"cited 2025 May 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04505826"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1017"},{"key":"e_1_3_7_45_1","volume-title":"ESMO Congress","author":"Lin NU","year":"2023","unstructured":"Lin NU, Borges V, Patel M, et al. Oral presentation 382MO: results from the phase 1\/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective er degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. ESMO Congress; Madrid, Spain; 2023 Oct 20\u201324."},{"key":"#cr-split#-e_1_3_7_46_1.1","unstructured":"Olema Pharmaceuticals Inc. OP-1250 (palazestrant) vs. standard of care for the treatment of ER+\/HER2- advanced breast cancer (OPERA-01). ClinicalTrials.gov identifier: NCT06016738. [Updated 2025 March 11"},{"key":"#cr-split#-e_1_3_7_46_1.2","unstructured":"cited 2025 May 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06016738"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3758"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.194"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4659"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj357"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00285"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000090985"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1023983032625"},{"key":"e_1_3_7_54_1","unstructured":"Olema Pharmaceuticals Inc. Phase 1b combo w\/ribociclib alpelisib or everolimus. ClinicalTrials.Gov identifier: NCT05508906. [Updated 2024 October; cited 2025 May 22]. https:\/\/clinicaltrials.gov\/study\/NCT05508906"},{"key":"#cr-split#-e_1_3_7_55_1.1","unstructured":"Pharmaceuticals O. Inc. A phase 1 study of oral OP-1250 in combination with palbociclib in HR+\/HER2- breast cancer patients. Clinicaltrials.Gov Identifier: NCT05266105. [Updated 2024 June 6"},{"key":"#cr-split#-e_1_3_7_55_1.2","unstructured":"cited 2025 May 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05266105"},{"key":"e_1_3_7_56_1","volume-title":"ESMO Breast Cancer Congress","author":"Borges VF","year":"2024","unstructured":"Borges VF, Chien J, Nunnery S, et al. Poster 212P: a phase Ib\/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. ESMO Breast Cancer Congress; Berlin, Germany; 2024 May 15\u201317."},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PS15-04"},{"key":"e_1_3_7_58_1","first-page":"S411","volume-title":"European Society for Medical Oncology Congress. Annals of Oncology","volume":"36","author":"Lin NU","year":"2025","unstructured":"Lin NU, Chien J, Ma C, et al. Poster P502: palazestrant (OP-1250) plus ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2\u2013) advanced breast cancer (ABC). European Society for Medical Oncology Congress. Annals of Oncology. Vol. 36; Berlin, Germany ; 2025 Oct 17\u201321. p. S411."},{"key":"e_1_3_7_59_1","unstructured":"Kisqali\u00ae (ribociclib). Prescribing information. Novartis; 2017. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kisqali.pdf"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2608863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:03:21Z","timestamp":1768208601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2608863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,14]]}},"alternative-id":["10.1080\/14796694.2025.2608863"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2608863","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}